Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why BerGenBio’s Bemcentinib Will Kick-Off UK’s COVID-19 ACCORD Program

New Direction For Phase II Anticancer Agent

Executive Summary

There is strong scientific rationale from US and UK research to support evaluating the selective AXL kinase inhibitor bemcentinib in the UK’s early-stage clinical study program, ACCORD, a new initiative to find potential COVID-19 therapies.

You may also be interested in...

Crescendo, BerGenBio Find Support For Cancer Studies

European biotech companies are finding diverse ways of finding support and financing to propel their potential first-in-class therapies into clinical studies, including sponsorship by patient charities as well as private placements.

BerGenBio raises funds to advance selective Axl kinase inhibitor

BerGenBio of Norway has raised NOK75 million (about $12.5 million) from new and existing investors through a private placement. The privately held company's lead drug candidate is BGB324, a first-in-class selective Axl kinase inhibitor, which is currently in Phase Ib studies to treat different cancers as monotherapy and in combination with other drugs.

Pipeline Watch: Late-Stage Candidate Bacterial And Viral Vaccines Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts